
Description:
This industry offers a 10-year forecast of the global respiratory inhaler devices market between 2015 and 2025. In terms of value, the market is expected to register a CAGR of 4.3% during the projected period. This study demonstrates market dynamics and trends in all seven regions that influence the current environment and future status of the respiratory inhaler devices market over the forecast period.

Report Description
This report examines the respiratory inhaler devices market for the period 2015–2025. The primary objective of the report is to offer insights into developments in the respiratory inhaler devices market that are significantly transforming global businesses and enterprises. Increasing prevalence of asthma, COPD and other respiratory diseases coupled with rising awareness is predicted to increase usages of respiratory inhaler devices worldwide. This is expected to bolster growth of the respiratory inhaler devices market over the next five to six years. Increasing demand for inhalation respiratory inhaler devices for controlling asthma and other respiratory disease, especially among children and elderly population, is expected to drive growth of respiratory inhaler devices market during the forecast period. Companies are focusing on regions and sections where prevalence of asthma, and chronic lung disease are increasing such as Asia Pacific and MEA.

The respiratory inhaler devices market report begins with an overview of the respiratory inhaler devices market in terms of value. This section includes analysis of key trends, drivers and restraints and opportunity, which are factors influencing growth of the respiratory inhaler devices market. Impact analysis of key growth drivers and restraints based on the weighted average model is included in the respiratory inhaler devices market report to better equip clients with crystal clear decision-making insights.

The global respiratory inhaler devices market is segmented on the basis of products type into dry powder inhaler (DPI), metered dose inhaler (MDI) and nebuliser. Nebuliser is further sub-segmented into compressed air nebuliser, ultrasonic nebuliser and mesh nebuliser. A detailed analysis has been provided for every segment and sub-segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

The next section of the report highlights respiratory inhaler devices adoption by region. It provides a market outlook for 2015–2025 and sets the forecast within the context of the respiratory inhaler devices market. The study discusses key regional trends contributing to growth of the respiratory inhaler devices market worldwide, as well as analyses the extent to which drivers are influencing this market in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and Middle East & Africa.

The above sections – by product type and region – evaluate the present scenario and growth prospects of the respiratory inhaler devices market for the period 2015 –2025. We have considered 2014 as the base year and provide data for the forecast period.

To ascertain respiratory inhaler devices market size, we have also considered revenue generated by manufacturers. The forecast presented here assesses the total revenue by value across the respiratory inhaler devices market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the respiratory inhaler devices market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis, based on supply side, downstream industry demand and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse on the basis of key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market and to identify the right opportunities across the respiratory inhaler devices market.

The respiratory inhaler devices segments in terms of product and regions are analysed in terms of Basis Point Share (BPS) to understand individual segment's relative contributions to market growth. This detailed
level of information is important for identification of various key trends in the respiratory inhaler devices market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the respiratory inhaler devices market.

To understand key growth segments in terms of growth and adoption for dry powder inhaler, metered dose inhaler and nebuliser across the globe in the near future, this industry developed the respiratory inhaler devices market 'Attractiveness Index'. The resulting index should help providers identify real market opportunities.

In the final section of the report, respiratory inhaler devices 'Competitive Landscape' is included to provide report audiences with a dashboard view, based on categories of providers in the value chain of the respiratory inhaler devices product portfolio and key differentiators. Key categories of providers covered in the report are respiratory inhaler devices manufacturers. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the respiratory inhaler devices value chain and the potential players for the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in respiratory inhaler devices marketplace.

Detailed profiles of the providers are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings and recent developments in the respiratory inhaler devices market. Key competitors covered in terms of manufacturers include AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.

Key Segments Covered

Product Type
Dry Powder Inhaler
Metered Dose Inhaler
Nebulizer
Ultrasonic Nebulizer
Compressed Air Nebulizer
Mesh Nebulizer
By Disease Indication
Asthma
COPD
Pulmonary Arterial Hypertension
Others Respiratory Disease
By Technology
Manually Operated Inhaler Devices
Digitally Operated Inhaler Devices

Key Regions/Countries Covered

North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Western Europe
EUS
Nordics
BENELUX
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific Excluding Japan (APEJ)
Greater China
India
ASEAN
Australia and New Zealand
Rest of APEJ
Japan
Middle East & Africa
GCC
South Africa
Israel
Turkey
Rest of MEA

Key Companies

AstraZeneca
Beximco Pharmaceuticals Ltd.
Boehringer Ingelheim GmbH
Cipla Ltd.
GlaxoSmithKline plc
Koninklijke Philips N.V.
Merck & Co., Inc.
OMRON Healthcare Europe B.V.
PARI Medical Holding
Teva Pharmaceutical Industries Ltd.

Contents:
1. Assumptions and Acronyms Used
2. Research Methodology
3. Executive Summary
4. Respiratory Inhaler Devices Market Overview
   4.1. Introduction
   4.2. Respiratory Inhaler Devices Market Definition
   4.3. Parent Market Overview
   4.4. Respiratory Inhaler Devices Market Product Overview
   4.5. Respiratory Inhaler Devices Market Dynamics
      4.5.1. Drivers
      4.5.2. Restraints
      4.5.3. Trends
5. Global Respiratory Inhaler Devices Market Analysis, By Product
   5.1. Introduction
   5.1.1. Y-o-Y Growth Comparison, By Product
   5.1.2. Market Share & Basis Point (BPS) Analysis, By Product
   5.2. Market Forecast, By Product
      5.2.1. Dry Powder Inhaler
         5.2.1.1. Absolute $ Opportunity
         5.2.1.2. Market Value and Volume Forecast, By Region
      5.2.2. Metered Dose Inhaler
         5.2.2.1. Absolute $ Opportunity
         5.2.2.2. Market Value and Volume Forecast, By Region
      5.2.3. Nebulizers
         5.2.3.1. Absolute $ Opportunity
         5.2.3.2. Market Value and Volume Forecast, By Region
         5.2.3.3. Compressed Air Nebulizers
         5.2.3.3.1. Absolute $ Opportunity
         5.2.3.3.2. Market Value and Volume Forecast, By Region
         5.2.3.4. Ultrasonic Nebulizers
5.2.3.4.1. Absolute $ Opportunity
5.2.3.4.2. Market Value and Volume Forecast, By Region
5.2.3.5. Mesh Nebulizers
5.2.3.5.1. Absolute $ Opportunity
5.2.3.5.2. Market Value and Volume Forecast, By Region
5.3. Market Attractiveness Analysis, By Product

6. Global Market Analysis, By Technology
6.1. Introduction
6.1.1. Y-o-Y Growth Comparison, By Technology
6.1.2. Market Share & Basis Point (BPS) Analysis, By Technology
6.2. Market Forecast, By Technology
6.2.1. Manually Operated Inhaler Devices
6.2.1.1. Absolute $ Opportunity
6.2.1.2. Market Value and Volume Forecast, By Region
6.2.2. Digitally Operated Inhaler Devices
6.2.2.1. Absolute $ Opportunity
6.2.2.2. Market Value and Volume Forecast, By Region
6.3. Market Attractiveness Analysis, By Technology

7. Global Market Analysis, By Disease Indication
7.1. Introduction
7.1.1. Y-o-Y Growth Comparison, By Disease Indication
7.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication
7.2. Market Forecast, By Disease Indication
7.2.1. Asthma
7.2.1.1. Absolute $ Opportunity
7.2.1.2. Market Value and Volume Forecast, By Region
7.2.2. Chronic Obstructive Pulmonary Disease (COPD)
7.2.2.1. Absolute $ Opportunity
7.2.2.2. Market Value and Volume Forecast, By Region
7.2.3. Pulmonary Arterial Hypertension
7.2.3.1. Absolute $ Opportunity
7.2.3.2. Market Value and Volume Forecast, By Region
7.2.4. Others
7.2.4.1. Absolute $ Opportunity
7.2.4.2. Market Value and Volume Forecast, By Region
7.3. Market Attractiveness Analysis, By Disease Indication

8. Global Respiratory Inhaler Devices Market Analysis, By Region
8.1. Introduction
8.1.1. Y-o-Y Growth Projections, By Region
8.1.2. Market Share & Basis Point (BPS) Analysis, By Region
8.2. Market Forecast, By Region
8.2.1. North America Market Value and Volume Forecast
8.2.2. Latin America Market Value and Volume Forecast
8.2.3. Western Europe Market Value and Volume Forecast
8.2.4. Eastern Europe Market Value and Volume Forecast
8.2.5. Asia Pacific Excluding Japan Market Value and Volume Forecast
8.2.6. Japan Market Value and Volume Forecast
8.2.7. MEA Market Value and Volume Forecast
8.3. Regional Attractiveness Analysis

9. North America Respiratory Inhaler Devices Market Analysis
9.1. Introduction
9.2. Y-o-Y Growth Projections, By Country
9.3. Market Share & Basis Point (BPS) Analysis, By Country
9.4. North America Market Forecast
9.5. Market Value and Volume Forecast, By Country
9.5.1. US Value and Volume Forecast
9.5.2. Canada Value and Volume Forecast
9.6. Market Value and Volume Forecast, By Product
9.6.1. Dry Powder Inhaler
9.6.2. Metered Dose Inhaler
9.6.3. Nebulizers
9.6.3.1. Compressed Air Nebulizers
9.6.3.2. Ultrasonic Nebulizers
9.6.3.3. Mesh Nebulizers
9.7. Market Value and Volume Forecast, By Technology
9.7.1. Manually Operated Inhaler Devices
9.7.2. Digitally Operated Inhaler Devices
9.8. Market Value and Volume Forecast, By Disease Indication
9.8.1. Asthma
9.8.2. Chronic Obstructive Pulmonary Disease (COPD)
9.8.3. Pulmonary Arterial Hypertension
9.8.4. Others
9.9. Market Attractiveness Analysis
9.9.1. By Country
9.9.2. By Product
9.9.3. By Technology
9.9.4. By Disease Indication

10. Latin America Respiratory Inhaler Devices Market Analysis
10.1. Introduction
10.2. Y-o-Y Growth Projections, By Country
10.3. Market Share & Basis Point (BPS) Analysis, By Country
10.4. Latin America Market Forecast
10.5. Market Value and Volume Forecast, By Country
10.5.1. Argentina Value and Volume Forecast
10.5.2. Brazil Value and Volume Forecast
10.5.3. Mexico Value and Volume Forecast
10.5.4. Rest of Latin America Value and Volume Forecast
10.6. Market Value and Volume Forecast, By Product
10.6.1. Dry Powder Inhaler
10.6.2. Metered Dose Inhaler
10.6.3. Nebulizers
10.6.3.1. Compressed Air Nebulizers
10.6.3.2. Ultrasonic Nebulizers
10.6.3.3. Mesh Nebulizers
10.7. Market Value and Volume Forecast, By Technology
10.7.1. Manually Operated Inhaler Devices
10.7.2. Digitally Operated Inhaler Devices
10.8. Market Value and Volume Forecast, By Disease Indication
10.8.1. Asthma
10.8.2. Chronic Obstructive Pulmonary Disease (COPD)
10.8.3. Pulmonary Arterial Hypertension
10.8.4. Others
10.9. Market Attractiveness Analysis
10.9.1. By Country
10.9.2. By Product
10.9.3. By Technology
10.9.4. By Disease Indication

11. Western Europe Respiratory Inhaler Devices Market Analysis
11.1. Introduction
11.2. Y-o-Y Growth Projections, By Country / Region
11.3. Market Share & Basis Point (BPS) Analysis, By Country
11.4. Western Europe Market Forecast
11.5. Market Value and Volume Forecast, By Country/Region
11.5.1. Germany Value and Volume Forecast
11.5.2. United Kingdom Value and Volume Forecast
11.5.3. France Value and Volume Forecast
11.5.4. Italy Value and Volume Forecast
11.5.5. Spain Value and Volume Forecast
11.5.6. NORDIC Value and Volume Forecast
11.5.7. BENELUX Value and Volume Forecast
11.5.8. Rest of Western Europe Value and Volume Forecast
11.6. Market Value and Volume Forecast, By Product
  11.6.1. Dry Powder Inhaler
  11.6.2. Metered Dose Inhaler
  11.6.3. Nebulizers
  11.6.3.1. Compressed Air Nebulizers
  11.6.3.2. Ultrasonic Nebulizers
  11.6.3.3. Mesh Nebulizers
11.7. Market Value and Volume Forecast, By Technology
  11.7.1. Manually Operated Inhaler Devices
  11.7.2. Digitally Operated Inhaler Devices
11.8. Market Value and Volume Forecast, By Disease Indication
  11.8.1. Asthma
  11.8.2. Chronic Obstructive Pulmonary Disease (COPD)
  11.8.3. Pulmonary Arterial Hypertension
  11.8.4. Others
11.9. Market Attractiveness Analysis
  11.9.1. By Country
  11.9.2. By Product
  11.9.3. By Technology
  11.9.4. By Disease Indication

12. Eastern Europe Respiratory Inhaler Devices Market Analysis
12.1. Introduction
12.2. Y-o-Y Growth Projections, By Country / Region
12.3. Market Share & Basis Point (BPS) Analysis, By Country
12.4. Eastern Europe Market Forecast
12.5. Market Value and Volume Forecast, By Country/Region
  12.5.1. Poland Value and Volume Forecast
  12.5.2. Russia Value and Volume Forecast
  12.5.3. Rest of Eastern Europe Value and Volume Forecast
12.6. Market Value and Volume Forecast, By Product
  12.6.1. Dry Powder Inhaler
  12.6.2. Metered Dose Inhaler
  12.6.3. Nebulizers
  12.6.3.1. Compressed Air Nebulizers
  12.6.3.2. Ultrasonic Nebulizers
  12.6.3.3. Mesh Nebulizers
12.7. Market Value and Volume Forecast, By Technology
  12.7.1. Manually Operated Inhaler Devices
  12.7.2. Digitally Operated Inhaler Devices
12.8. Market Value and Volume Forecast, By Disease Indication
  12.8.1. Asthma
  12.8.2. Chronic Obstructive Pulmonary Disease (COPD)
  12.8.3. Pulmonary Arterial Hypertension
  12.8.4. Others
12.9. Market Attractiveness Analysis
  12.9.1. By Country
  12.9.2. By Product
  12.9.3. By Technology
  12.9.4. By Disease Indication

13. Asia Pacific Excluding Japan Respiratory Inhaler Devices Market Analysis
13.1. Introduction
13.2. Y-o-Y Growth Projections, By Country
13.3. Market Share & Basis Point (BPS) Analysis, By Country
13.4. Asia Pacific Excluding Japan Market Forecast
13.5. Market Value and Volume Forecast, By Country/Region
  13.5.1. Greater China Value and Volume Forecast
  13.5.2. India Value and Volume Forecast
  13.5.3. ASEAN Value and Volume Forecast
  13.5.4. Australia and New Zealand Value and Volume Forecast
  13.5.5. Rest of APAC Value and Volume Forecast
13.6. Market Value and Volume Forecast, By Product
13.6.1. Dry Powder Inhaler
13.6.2. Metered Dose Inhaler
13.6.3. Nebulizers
13.6.3.1. Compressed Air Nebulizers
13.6.3.2. Ultrasonic Nebulizers
13.6.3.3. Mesh Nebulizers
13.6.4. Others
13.7. Market Value and Volume Forecast, By Technology
13.7.1. Manually Operated Inhaler Devices
13.7.2. Digitally Operated Inhaler Devices
13.8. Market Value and Volume Forecast, By Disease Indication
13.8.1. Asthma
13.8.2. Chronic Obstructive Pulmonary Disease (COPD)
13.8.3. Pulmonary Arterial Hypertension
13.9. Market Attractiveness Analysis
13.9.1. By Country
13.9.2. By Product
13.9.3. By Technology
13.9.4. By Disease Indication

14. Japan Respiratory Inhaler Devices Market Analysis
14.1. Introduction
14.2. Y-o-Y Growth Projections, By Country
14.3. Market Share & Basis Point (BPS) Analysis, By Country
14.4. Japan Market Forecast
14.5. Market Value and Volume Forecast, By Product
14.5.1. Dry Powder Inhaler
14.5.2. Metered Dose Inhaler
14.5.3. Nebulizers
14.5.3.1. Compressed Air Nebulizers
14.5.3.2. Ultrasonic Nebulizers
14.5.3.3. Mesh Nebulizers
14.6. Market Value and Volume Forecast, By Technology
14.6.1. Manually Operated Inhaler Devices
14.6.2. Digitally Operated Inhaler Devices
14.7. Market Value and Volume Forecast, By Disease Indication
14.7.1. Asthma
14.7.2. Chronic Obstructive Pulmonary Disease (COPD)
14.7.3. Pulmonary Arterial Hypertension
14.7.4. Others
14.8. Market Attractiveness Analysis
14.8.1. By Country
14.8.2. By Product
14.8.3. By Technology
14.8.4. By Disease Indication

15. MEA Respiratory Inhaler Devices Market Analysis
15.1. Introduction
15.2. Y-o-Y Growth Projections, By Country / Region
15.3. Market Share & Basis Point (BPS) Analysis, By Country
15.4. MEA Market Forecast
15.5. Market Value and Volume Forecast, By Country/Region
15.5.1. GCC Value and Volume Forecast
15.5.2. North Africa Value and Volume Forecast
15.5.3. South Africa Value and Volume Forecast
15.5.4. Rest of MEA Value and Volume Forecast
15.6. Market Value and Volume Forecast, By Product
15.6.1. Dry Powder Inhaler
15.6.2. Metered Dose Inhaler
15.6.3. Nebulizers
15.6.3.1. Compressed Air Nebulizers
15.6.3.2. Ultrasonic Nebulizers
15.6.3.3. Mesh Nebulizers
15.7. Market Value and Volume Forecast, By Technology
15.7.1. Manually Operated Inhaler Devices
15.7.2. Digitally Operated Inhaler Devices
15.8. Market Value and Volume Forecast, By Disease Indication
15.8.1. Asthma
15.8.2. Chronic Obstructive Pulmonary Disease (COPD)
15.8.3. Pulmonary Arterial Hypertension
15.8.4. Others
15.9. Market Attractiveness Analysis
15.9.1. By Country
15.9.2. By Product
15.9.3. By Technology
15.9.4. By Disease Indication
15.10. Drivers & Restraints: Impact Analysis

16. Competition Landscape
16.1. Major Mergers and Acquisitions
16.2. Company Profiles
16.2.1. Revenue
16.2.2. Products/Brand Offerings
16.2.3. Company Highlights
16.2.4. Strategies
16.3. AstraZeneca plc
16.4. Beximco Pharmaceuticals Ltd
16.5. Boehringer Ingelheim GmbH
16.6. Cipla Ltd
16.7. GlaxoSmithKline plc
16.8. Koninklijke Philips N.V.
16.9. Merck & Co., Inc.
16.10. OMRON Healthcare Europe B.V.
16.11. PARI Medical Holding
16.12. Teva Pharmaceutical Industries Ltd

Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address:   http://www.researchandmarkets.com/reports/3494430/
Office Code:   SCH38LQS

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Formats</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 7500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  []  Mrs  []  Dr  []  Miss  []  Ms  []  Prof  []
First Name: ___________________________________________  Last Name: ___________________________________________
Email Address: * _______________________________________
Job Title: _______________________________________
Organisation: _______________________________________
Address: _______________________________________
City: _______________________________________
Postal / Zip Code: _______________________________________
Country: _______________________________________
Phone Number: _______________________________________
Fax Number: _______________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp